Jane Street Group Adds $13M in Adaptive Biotechnologies Corporation ($ADPT)
Key Points
- Wall Street's consensus rating on $ADPT is Strong Buy and an average price target of $20.14.
- $ADPT last traded around $18.73.
Jane Street Group acquired a new position in Adaptive Biotechnologies Corporation ($ADPT), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 682,182 shares of Adaptive Biotechnologies Corporation. Jane Street Group's holdings in Adaptive Biotechnologies Corporation were worth $12.78 million as of its most recent filing.
Adaptive Biotechnologies Corporation ($ADPT) Stock
Adaptive Biotechnologies Corporation Earnings
Analysts Set New Price Targets
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.